

Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

CD3 Antibody, anti-human, APC, REAfinity™

RRID:AB_2725963

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-135, RRID:AB_2725963

Antibody Information

URL: http://antibodyregistry.org/AB_2725963

Proper Citation: Miltenyi Biotec Cat# 130-113-135, RRID:AB_2725963

Target Antigen: CD3

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-109-462. (RRID:AB_2657063).

Antibody Name: CD3 Antibody, anti-human, APC, REAfinity™

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: clone REA613

Antibody ID: AB_2725963

Vendor: Miltenyi Biotec

Catalog Number: 130-113-135

Record Creation Time: 20250820T015201+0000

Record Last Update: 20250820T120409+0000

Ratings and Alerts

No rating or validation information has been found for CD3 Antibody, anti-human, APC, REAfinity™.

No alerts have been found for CD3 Antibody, anti-human, APC, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Ghasabeh AS, et al. (2026) Allogeneic CD56 + cell infusion as a bridge to hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a phase I clinical trial. Cancer immunology, immunotherapy : CII, 75(4).

Fontana L, et al. (2025) Multiplex base editing of BCL11A regulatory elements to treat sickle cell disease. Cell reports. Medicine, 102376.

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. Cell reports. Medicine, 5(11), 101823.